FRAXA’s mission is to discover specific treatments and ultimately a cure for Fragile X syndrome, aiming to transition practical treatment into current medical practice quickly. They prioritize projects with clear, practical applications, emphasizing results sharing in a timely manner. By funding research grants and fellowships globally and partnering with biomedical and pharmaceutical companies, FRAXA bridges the gap between research discoveries and treatments, benefiting individuals affected by Fragile X and potentially those with autism, Alzheimer's, and other brain disorders.
FRAXA Research Foundation focuses on advancing research that promises to lead to new and improved treatments and ultimately a cure for Fragile X syndrome. They place particular importance on disease-modifying therapeutics derived from an understanding of Fragile X disease mechanisms. The foundation supports clinical trials as its highest priority, alongside translational research and early-stage investigations. FRAXA adapts its funding priorities based on the current research landscape and past bottlenecks in the research process, with a historical emphasis on overcoming issues like basic disease mechanism understanding and resource constraints. Recently, FRAXA has shifted its focus towards overcoming bottlenecks in preclinical validation and moving towards more efficient validation of promising drug treatment strategies to accelerate the pace of Fragile X research and treatment development.
irure incididunt et veniam sint anim consequat duis laboris ut fugiat pariatur sunt minim consequat in do sint ut amet veniam pariatur dolore ex fugiat Lorem enim ullamco id cupidatat fugiat culpa Lorem adipisicing elit magna in elit magna ex sint ea tempor ad ipsum amet esse duis in nostrud sunt reprehenderit labore esse dolore nulla minim enim minim sint officia sint quis exercitation exercitation sit ullamco ipsum proident laboris ea laborum duis voluptate elit ad qui magna consequat aliquip in